YOKNEAM, Israel, April 20, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (Nasdaq:LMNS), the world's largest energy-based medical company for surgical, ophthalmology, and aesthetic applications announced today that the company will feature its dual CO2 laser technology at an educational symposium: "Challenging Cases Helped by Dual CO2 Laser Modalities" at the Combined Otolaryngology Spring Meetings (COSM) 2015, being held in Boston, Mass., from April 22 – 26, 2015.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=32218
Marc Remacle, M.D., Ph.D., Department of ORL and Head & Neck Surgery, University Hospital of Mont-Godinne, Belgium, and moderator of the Lumenis symposium, commented: "Providing precise, individualized patient care can be challenging for ENT surgeons because of the broad spectrum of surgical situations that can arise during the procedure. With the combined modality of the CO2 laser and the easy shift between free beam and fiber deliveries I can delicately address any clinical challenge while preserving healthy tissue, which is very important for the patient's recovery and comfort."
The AcuPulse DUO is the only integrated CO2 laser system that offers seamless adjustment between the two therapeutic modalities. The DUO platform is accompanied by a wide range of surgical tools, along with cost effective fibers that feature renewable tips, aiming beam and high energy transmission. The DUO CO2 laser system is designed for smart tissue management and for optimal treatment of hard-to-reach anatomy. Thousands of patients worldwide have experienced better care with surgeons who chose to enhance their surgical capabilities with the DUO modality.
"Precision is a critical factor for attaining zero tumor margins," said Joshua Schindler, M.D., Associate Professor and Medical Director, Northwest Center for Voice and Swallowing, Oregon Health & Science University. "Seeing the margin and surgical plane can be achieved by the unique capabilities of the fiber, which enables to complete surgical procedures, leaving no disease behind."
"The DUO technology represents an important breakthrough in CO2 laser surgery for ear, nose and throat conditions," said Tzipi Ozer-Armon, CEO of Lumenis. "More head and neck surgeons are recognizing the importance of having both free beam and fiber delivery options ready for challenging clinical cases, and our goal is to preserve the innovative approach and bring to market future advances in the field."
Lumenis will be exhibiting at booth #319 throughout COSM. Click here for a schedule highlighting the company's educational events.
You are invited to register to the breakfast symposium and ensure your spot is saved.
Thursday, April 23, 2015, The Public Garden Room at the Sheraton Hotel
|6:30 – 8:00 AM||Breakfast Symposium: "Challenging C Modalities"|
|Marc Remacle, M.D., Ph.D. (moderator)|
|University Hospital of Mont-Godinne,|
|Joshua Schindler, M.D.|
|Oregon Health & Science University|
|Paul Castellanos, M.D.|
|University of Alabama at Birmingham|
|Abie Mendelsohn, M.D.|
|University of California, Los Angeles|
Lumenis also invites COSM attendees to meet the experts at the Lumenis booth during the noon hour on Thursday and Friday for an opportunity to engage in one-on-one dialogue and share best practices and experiences.
Lumenis (Nasdaq:LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. For more information visit: www.lumenis.com
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon our management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Glenn Silver Lazar Partners Ltd. (646) 871-8485